X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs CIPLA - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA CIPLA GLENMARK PHARMA/
CIPLA
 
P/E (TTM) x 13.9 44.1 31.4% View Chart
P/BV x 3.9 3.6 106.9% View Chart
Dividend Yield % 0.3 0.4 92.6%  

Financials

 GLENMARK PHARMA   CIPLA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-16
CIPLA
Mar-17
GLENMARK PHARMA/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,262622 202.9%   
Low Rs672458 146.5%   
Sales per share (Unadj.) Rs270.6181.9 148.8%  
Earnings per share (Unadj.) Rs24.912.9 193.3%  
Cash flow per share (Unadj.) Rs34.429.3 117.4%  
Dividends per share (Unadj.) Rs2.002.00 100.0%  
Dividend yield (eoy) %0.20.4 55.9%  
Book value per share (Unadj.) Rs151.3155.7 97.2%  
Shares outstanding (eoy) m282.16804.51 35.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.63.0 120.3%   
Avg P/E ratio x38.942.0 92.6%  
P/CF ratio (eoy) x28.118.4 152.5%  
Price / Book Value ratio x6.43.5 184.1%  
Dividend payout %8.015.5 51.7%   
Avg Mkt Cap Rs m272,778434,516 62.8%   
No. of employees `00010.023.0 43.5%   
Total wages/salary Rs m13,78226,338 52.3%   
Avg. sales/employee Rs Th7,614.96,349.1 119.9%   
Avg. wages/employee Rs Th1,374.81,143.0 120.3%   
Avg. net profit/employee Rs Th700.2449.3 155.8%   
INCOME DATA
Net Sales Rs m76,340146,302 52.2%  
Other income Rs m3562,287 15.6%   
Total revenues Rs m76,696148,589 51.6%   
Gross profit Rs m14,17224,758 57.2%  
Depreciation Rs m2,69113,229 20.3%   
Interest Rs m1,7891,594 112.2%   
Profit before tax Rs m10,04812,222 82.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,0281,798 168.5%   
Profit after tax Rs m7,01910,354 67.8%  
Gross profit margin %18.616.9 109.7%  
Effective tax rate %30.114.7 204.9%   
Net profit margin %9.27.1 129.9%  
BALANCE SHEET DATA
Current assets Rs m59,09687,370 67.6%   
Current liabilities Rs m40,01833,081 121.0%   
Net working cap to sales %25.037.1 67.3%  
Current ratio x1.52.6 55.9%  
Inventory Days Days7587 86.2%  
Debtors Days Days11962 191.3%  
Net fixed assets Rs m39,075111,567 35.0%   
Share capital Rs m2821,609 17.5%   
"Free" reserves Rs m30,281123,645 24.5%   
Net worth Rs m42,703125,254 34.1%   
Long term debt Rs m24,87336,454 68.2%   
Total assets Rs m111,026209,532 53.0%  
Interest coverage x6.68.7 76.3%   
Debt to equity ratio x0.60.3 200.1%  
Sales to assets ratio x0.70.7 98.5%   
Return on assets %7.95.7 139.1%  
Return on equity %16.48.3 198.8%  
Return on capital %17.58.5 206.1%  
Exports to sales %43.334.2 126.5%   
Imports to sales %7.48.3 89.1%   
Exports (fob) Rs m33,04450,050 66.0%   
Imports (cif) Rs m5,67212,203 46.5%   
Fx inflow Rs m36,94551,066 72.3%   
Fx outflow Rs m61,06617,678 345.4%   
Net fx Rs m-24,12233,388 -72.2%   
CASH FLOW
From Operations Rs m3,44923,824 14.5%  
From Investments Rs m-8,802-13,127 67.1%  
From Financial Activity Rs m6,986-13,239 -52.8%  
Net Cashflow Rs m934-2,478 -37.7%  

Share Holding

Indian Promoters % 48.3 16.0 301.9%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 6.9 12.2 56.6%  
FIIs % 34.4 23.7 145.1%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.5 26.2 40.1%  
Shareholders   56,727 161,166 35.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DR. DATSONS LABS  STRIDES SHASUN LTD  J.B.CHEMICALS  JUBILANT LIFE SCIENCES  BIOCON LTD  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

Feb 15, 2017

Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS